• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by OPKO Health Inc.

    11/13/24 4:30:24 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPK alert in real time by email
    SC 13G 1 tm2427812d16_sc13g.htm SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

     

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    OPKO Health, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.01 par value

     

    (Title of Class of Securities)

     

    68375N103

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of event which requires filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

      x Rule 13d-1(b)
      ¨ Rule 13d-1(c)
      ¨ Rule 13d-1(d)

     

    (Page 1 of 8 Pages)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     

     

     

    CUSIP No. 68375N103

     

    13G Page 2 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Rubric Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    48,706,640 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    48,706,640 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    48,706,640 shares of Common Stock

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.98%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

    CUSIP No. 68375N103

     

    13G Page 3 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    David Rosen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    48,706,640 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    48,706,640 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    48,706,640 shares of Common Stock

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.98%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 68375N103

     

    13G Page 4 of 8 Pages

     

    Item 1(a). NAME OF ISSUER:
     
      The name of the issuer is OPKO Health, Inc. (the "Issuer").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Issuer's principal executive offices are located at 4400 Biscayne Blvd, Miami, FL 33137

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i) Rubric Capital Management LP ("Rubric Capital"), the investment adviser to certain investment funds and/or accounts (collectively, the "Rubric Funds") that hold the shares of Common Stock (as defined in Item 2(d) below) reported herein; and
         
      (ii) David Rosen ("Mr. Rosen"), Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the principal business office of each of the Reporting Persons is 155 East 44th St, Suite 1630, New York, NY 10017.

     

    Item 2(c). CITIZENSHIP:
       
      Rubric Capital is a Delaware limited partnership. Mr. Rosen is a citizen of the United States of America.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, $0.01 par value (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      68375N103

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,

     

     

     

    CUSIP No. 03969K108

     

    13G Page 5 of 8 Pages

     

      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) x Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________________________

     

    Item 4. OWNERSHIP.
       
     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

    The percentage set forth in Row (11) of the cover page for each of the Reporting Persons is based on the 697,375,055 shares of Common Stock outstanding as of August 1, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 filed with the Securities and Exchange Commission on August 7, 2024.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2. Rubric Capital Master Fund LP, a Rubric Fund, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.
           

     

     

    CUSIP No. 03969K108

     

    13G Page 6 of 8 Pages

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

      

    CUSIP No. 03969K108

     

    13G Page 7 of 8 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of our knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    DATED: November 13, 2024

     

    RUBRIC CAPITAL MANAGEMENT LP  
       
       
    By: /s/ Michael Nachmani  
    Name: Michael Nachmani  
    Title: Chief Operating Officer  
       
    /s/ David Rosen  
    DAVID ROSEN  

     

     

     

    CUSIP No. 03969K108

     

    13G Page 8 of 8 Pages

     

    EXHIBIT 1

     

    JOINT ACQUISITION STATEMENT
    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    DATED: November 13, 2024

     

    RUBRIC CAPITAL MANAGEMENT LP  
       
       
    By: /s/ Michael Nachmani  
    Name: Michael Nachmani  
    Title: Chief Operating Officer  
       
    /s/ David Rosen  
    DAVID ROSEN  

     

     

     

    Get the next $OPK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPK

    DatePrice TargetRatingAnalyst
    4/29/2026Outperform → Mkt Perform
    Barrington Research
    11/20/2025Neutral
    Analyst
    10/31/2025$1.60Buy → Hold
    Jefferies
    4/25/2025Neutral
    Analyst
    6/29/2023$2.00Mkt Perform → Outperform
    Barrington Research
    12/15/2022$3.00Buy
    H.C. Wainwright
    1/24/2022Outperform → Market Perform
    Barrington Research
    More analyst ratings

    $OPK
    SEC Filings

    View All

    SEC Form DEFA14A filed by OPKO Health Inc.

    DEFA14A - OPKO HEALTH, INC. (0000944809) (Filer)

    5/15/26 4:38:03 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by OPKO Health Inc.

    DEFA14A - OPKO HEALTH, INC. (0000944809) (Filer)

    4/30/26 4:03:22 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by OPKO Health Inc.

    DEF 14A - OPKO HEALTH, INC. (0000944809) (Filer)

    4/30/26 4:01:43 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

    Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models  Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting WESTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), will announce preclinical data demonstrating the in vivo generation of CAR-T cells and deep systemic B-cell depletion achieved with its MDX3001 candidate in animal models. The data, generated using ModeX's CD3xCD28 antibody-conjugated lipid nanoparticle (LNP)/mRNA platform, will be presented at the ASGCT 2026 Annual Meeting, being held May 11-15 in Bo

    5/12/26 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

    MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an amendment to its agreement with Nicoya Therapeutics (Macau) Limited, an affiliate of Nicoya Therapeutics (Nicoya), which grants OPKO an equity stake in Nicoya and reinforces Nicoya's commitment to commercialize RAYALDEE® in Greater China. RAYALDEE is approved in Macau, and the companies expect regulatory approvals in China and related territories in 2027. In June 2021, EirGen and Nicoya entered into an agreement for the development and commercialization in Greater China of RAYALDEE® for the treatment of secondary hyperparath

    4/30/26 8:30:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

    ELMWOOD PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- BioReference® Health LLC, an OPKO Health, Inc. company and a trusted provider of diagnostic testing in the United States, today announced the launch of BioReference DirectTM, a new digital health platform designed to give consumers direct access to high-quality laboratory testing. Leveraging 45 years of laboratory testing expertise, along with an established footprint of patient service centers across New York and New Jersey, BioReference is expanding its capabilities to deliver a seamless, end-to-end digital experience. BioReference Direct enables individuals to select from a menu of available laboratory tests online, all supported b

    4/30/26 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Paganelli John A

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    3/20/26 4:25:05 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Uppaluri Subbarao V

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    3/20/26 4:16:55 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Uppaluri Subbarao V

    3 - OPKO HEALTH, INC. (0000944809) (Issuer)

    3/20/26 4:10:17 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Opko Health downgraded by Barrington Research

    Barrington Research downgraded Opko Health from Outperform to Mkt Perform

    4/29/26 7:41:04 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst initiated coverage on Opko Health

    Analyst initiated coverage of Opko Health with a rating of Neutral

    11/20/25 8:08:07 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opko Health downgraded by Jefferies with a new price target

    Jefferies downgraded Opko Health from Buy to Hold and set a new price target of $1.60

    10/31/25 8:18:38 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & Chairman Frost Phillip Md Et Al bought $768,807 worth of shares (580,000 units at $1.33) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/21/25 5:07:09 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $771,328 worth of shares (580,000 units at $1.33) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/20/25 6:10:53 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $759,115 worth of shares (580,000 units at $1.31) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/19/25 5:02:21 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    Leadership Updates

    Live Leadership Updates

    View All

    OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

    WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera

    9/23/24 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jon Cohen and Michael Hansen Join Talkspace's Board of Directors

    NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (NASDAQ:TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company's board of directors and approved all other shareholder proposals during the company's first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Health (NASDAQ:OPK). Dr. Cohen brings 30 years of healthcare industry strategy and operating experience to Talkspace's board of directors. He succeeds Jeffrey Crowe as an independent Class I Director with a term expiring in 2025. Additionally, the Company's board appointed C

    9/15/22 4:05:00 PM ET
    $OPK
    $TALK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services

    OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx

    MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO's BioReference Laboratories. Ms. Stueland joins GeneDx from Invitae Corporation (NYSE:NVTA), where she served most recently as Chief Commercial Officer, establishing the corporate brand as Invitae evolved from a private company to a public entity with a market capitalization exceeding $6 billion.  "We're thrilled to have Katherine lead the team at GeneDx, which has served clinicians and patients for more than two decades with novel and differentiated technologies for di

    6/22/21 8:00:00 AM ET
    $OPK
    $NVTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $OPK
    Financials

    Live finance-specific insights

    View All

    OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

    MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first quarter of 2026 and recent weeks included the following: Initiated and completed first dose cohort of MDX2301 Phase 1 clinical trial for the prevention of COVID-19. MDX2301 is a tetravalent bispecific antibody that neutralizes all known variants of SARS-CoV-2 and also has the potential to delay resistance by emerging variants. The Phase 1 clinical trial (NCT07445971) is evaluating the safety, pharmacokinetics and tolerability of MDX2301 administered via different routes in healthy volunteers

    4/28/26 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026

    MIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three months ended March 31, 2026 after the close of the U.S. financial markets on Tuesday, April 28, 2026. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 28th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants

    4/21/26 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

    MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX's MSTAR technology platform with Regeneron's proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several clinical indications. ModeX received an upfront

    2/26/26 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by OPKO Health Inc.

    SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/15/24 4:39:33 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by OPKO Health Inc.

    SC 13G - OPKO HEALTH, INC. (0000944809) (Subject)

    11/13/24 4:30:24 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OPKO Health Inc.

    SC 13G/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/12/24 4:54:06 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care